PMID- 38239364
OWN - NLM
STAT- MEDLINE
DCOM- 20240122
LR  - 20240403
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Dendritic cells: the yin and yang in disease progression.
PG  - 1321051
LID - 10.3389/fimmu.2023.1321051 [doi]
LID - 1321051
AB  - Dendritic cells (DCs) are antigen presenting cells that link innate and adaptive 
      immunity. DCs have been historically considered as the most effective and potent 
      cell population to capture, process and present antigens to activate naive T 
      cells and originate favorable immune responses in many diseases, such as cancer. 
      However, in the last decades, it has been observed that DCs not only promote 
      beneficial responses, but also drive the initiation and progression of some 
      pathologies, including inflammatory bowel disease (IBD). In line with those 
      notions, different therapeutic approaches have been tested to enhance or impair 
      the concentration and role of the different DC subsets. The blockade of 
      inhibitory pathways to promote DCs or DC-based vaccines have been successfully 
      assessed in cancer, whereas the targeting of DCs to inhibit their functionality 
      has proved to be favorable in IBD. In this review, we (a) described the general 
      role of DCs, (b) explained the DC subsets and their role in immunogenicity, (c) 
      analyzed the role of DCs in cancer and therapeutic approaches to promote 
      immunogenic DCs and (d) analyzed the role of DCs in IBD and therapeutic 
      approaches to reduced DC-induced inflammation. Therefore, we aimed to highlight 
      the "yin-yang" role of DCs to improve the understand of this type of cells in 
      disease progression.
CI  - Copyright (c) 2024 Jimenez-Cortegana, Palomares, Alba, Santa-Maria, de la 
      Cruz-Merino, Sanchez-Margalet and Lopez-Enriquez.
FAU - Jimenez-Cortegana, Carlos
AU  - Jimenez-Cortegana C
AD  - Department of Medical Biochemistry, Molecular Biology and Immunology, School of 
      Medicine, University of Seville, Seville, Spain.
FAU - Palomares, Francisca
AU  - Palomares F
AD  - Department of Medical Biochemistry, Molecular Biology and Immunology, School of 
      Medicine, University of Seville, Seville, Spain.
FAU - Alba, Gonzalo
AU  - Alba G
AD  - Department of Medical Biochemistry, Molecular Biology and Immunology, School of 
      Medicine, University of Seville, Seville, Spain.
FAU - Santa-Maria, Consuelo
AU  - Santa-Maria C
AD  - Department of Biochemistry and Molecular Biology, School of Pharmacy, University 
      of Seville, Seville, Spain.
FAU - de la Cruz-Merino, Luis
AU  - de la Cruz-Merino L
AD  - Clinical Oncology Dept. Medicine Department, University of Seville, Virgen 
      Macarena University Hospital, Seville, Spain.
FAU - Sanchez-Margalet, Victor
AU  - Sanchez-Margalet V
AD  - Department of Medical Biochemistry, Molecular Biology and Immunology, School of 
      Medicine, University of Seville, Seville, Spain.
FAU - Lopez-Enriquez, Soledad
AU  - Lopez-Enriquez S
AD  - Department of Medical Biochemistry, Molecular Biology and Immunology, School of 
      Medicine, University of Seville, Seville, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240104
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Humans
MH  - Dendritic Cells
MH  - Adaptive Immunity
MH  - *Neoplasms/metabolism
MH  - *Inflammatory Bowel Diseases
MH  - Disease Progression
PMC - PMC10794555
OTO - NOTNLM
OT  - cancer
OT  - dendritic cell
OT  - immunity
OT  - inflammation
OT  - inflammatory bowel disease
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/19 06:42
MHDA- 2024/01/22 06:42
PMCR- 2023/01/01
CRDT- 2024/01/19 03:38
PHST- 2023/10/16 00:00 [received]
PHST- 2023/12/12 00:00 [accepted]
PHST- 2024/01/22 06:42 [medline]
PHST- 2024/01/19 06:42 [pubmed]
PHST- 2024/01/19 03:38 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1321051 [doi]
PST - epublish
SO  - Front Immunol. 2024 Jan 4;14:1321051. doi: 10.3389/fimmu.2023.1321051. 
      eCollection 2023.